Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...
The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
Axonics Modulation Technologies (AXNX) intends to raise $100 million from the sale of its common stock in an IPO, per an amended registration statement.The company is developing a sacral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback